Categories: News

Bybit Exclusive: DefiTuna (TUNA) to List on Bybit Spot

DUBAI, UAE, July 30, 2025 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, announced the exclusive listing of DefiTuna (TUNA) on Bybit Spot in the Main Trading Zone. The native token of innovative Solana-based protocol DefiTuna, TUNA is the star of one of the most anticipated token generation events (TGE) in DeFi this season.

- Advertisement -

Starting July 30, 2025 at 3:00 PM UTC, Bybit user can trade TUNA/USDT on Spot. All transactions will be processed through the Solana network, with TUNA also supported by Bybit Spot’s automated Grid Bot functionality from launch.

- Advertisement -

Eligible Bybit users will also get to join the TUNA Token Splash, exclusive on Bybit.

- Advertisement -

TUNA is a revenue sharing token of Fusion AMM and DefiTuna. DefiTuna operates as an Automated Market Maker (AMM) built on Solana that empowers Liquidity Providers with unique capabilities. The platform allows users to take leveraged positions—both long and short—to potentially maximize profitability or create effective hedging strategies. By supporting both leverage trading and lending on-chain, DefiTuna delivers a seamless experience for Liquidity Providers and Lenders within a unified ecosystem.

- Advertisement -

DefiTuna is the first decentralized leverage aggregation protocol within the Solana ecosystem to integrate three key components: Concentrated Liquidity Market Making (CLMM), leverage trading, and lending. As a DeFi platform focused on concentrated liquidity market making and leveraged position management, DefiTuna’s innovative product positioning and user-friendly design occupy a unique position in the Solana ecosystem.

- Advertisement -

This exclusive partnership positions Bybit as the primary destination for TUNA trading, providing users with first access to this innovative AMM protocol.

- Advertisement -

#Bybit / #TheCryptoArk 

- Advertisement -

About Bybit

- Advertisement -

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 70 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

- Advertisement -

For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit’s Communities and Social Media

- Advertisement -

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

- Advertisement -

Logo – https://mma.prnewswire.com/media/2267288/Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/bybit-exclusive-defituna-tuna-to-list-on-bybit-spot-302517502.html

- Advertisement -

Recent Posts

Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: Ocular Therapeutix, Inc. BEDFORD, Mass., Feb. 06, 2026…

2 hours ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI,…

2 hours ago

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing…

2 hours ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies

AlUla, Saudi Arabia, Feb. 7, 2026 /PRNewswire/ -- The second edition of the AlUla Conference…

2 hours ago

Roches fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint…

2 hours ago

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

February 06, 2026 17:17 ET  | Source: Lexicon Pharmaceuticals, Inc. THE WOODLANDS, Texas, Feb. 06,…

2 hours ago